{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:03:11Z","timestamp":1791295391677,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2005,8,11]],"date-time":"2005-08-11T00:00:00Z","timestamp":1123718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,8,11]],"date-time":"2005-08-11T00:00:00Z","timestamp":1123718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2005,10,1]]},"DOI":"10.1038\/sj.leu.2403905","type":"journal-article","created":{"date-parts":[[2005,8,11]],"date-time":"2005-08-11T07:53:00Z","timestamp":1123746780000},"page":"1729-1738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside"],"prefix":"10.1038","volume":"19","author":[{"given":"B","family":"Bruno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Rotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Multiple Myeloma Research Foundation","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,8,11]]},"reference":[{"key":"BF2403905_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0002-9343(98)00080-1","volume":"104","author":"HJ Cohen","year":"1998","unstructured":"Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS . Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 1998; 104: 439\u2013444.","journal-title":"Am J Med"},{"key":"BF2403905_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91\u201397.","journal-title":"N Engl J Med"},{"key":"BF2403905_CR3","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","volume":"102","author":"DG Maloney","year":"2003","unstructured":"Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447\u20133454.","journal-title":"Blood"},{"key":"BF2403905_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S1470-2045(04)01511-6","volume":"5","author":"B Bruno","year":"2004","unstructured":"Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A et al. New drugs for reatment of multiple myeloma. Lancet Oncol 2004; 5: 430\u2013442.","journal-title":"Lancet Oncol"},{"key":"BF2403905_CR5","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","volume":"93","author":"JS Damiano","year":"1999","unstructured":"Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS . Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658\u20131667.","journal-title":"Blood"},{"key":"BF2403905_CR6","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.4049\/jimmunol.168.5.2544","volume":"168","author":"KH Shain","year":"2002","unstructured":"Shain KH, Landowski TH, Dalton WS . Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol 2002; 168: 2544\u20132553.","journal-title":"J Immunol"},{"key":"BF2403905_CR7","doi-asserted-by":"publisher","first-page":"11107","DOI":"10.1073\/pnas.95.19.11107","volume":"95","author":"TK Sengupta","year":"1998","unstructured":"Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB . Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases. Proc Natl Acad Sci USA 1998; 95: 11107\u201311112.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2403905_CR8","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.4049\/jimmunol.159.5.2212","volume":"159","author":"A Ogata","year":"1997","unstructured":"Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997; 159: 2212\u20132221.","journal-title":"J Immunol"},{"key":"BF2403905_CR9","doi-asserted-by":"publisher","first-page":"5991","DOI":"10.1038\/sj.onc.1204833","volume":"20","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Nakamura N, Chauhan D, Anderson KC . Biologic sequelae of interleukin-6 induced PI3-K\/Akt signaling in multiple myeloma. Oncogene 2001; 20: 5991\u20136000.","journal-title":"Oncogene"},{"key":"BF2403905_CR10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1182\/blood.V98.2.428","volume":"98","author":"K Podar","year":"2001","unstructured":"Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98: 428\u2013435.","journal-title":"Blood"},{"key":"BF2403905_CR11","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096\u20131103.","journal-title":"Nat Med"},{"key":"BF2403905_CR12","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","volume":"20","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC . The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20: 4519\u20134527.","journal-title":"Oncogene"},{"key":"BF2403905_CR13","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.1038\/sj.onc.1205664","volume":"21","author":"CS Mitsiades","year":"2002","unstructured":"Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1\/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002; 21: 5673\u20135683.","journal-title":"Oncogene"},{"key":"BF2403905_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.4161\/cbt.1.5.174","volume":"1","author":"T Hideshima","year":"2002","unstructured":"Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther 2002; 1: 539\u2013544.","journal-title":"Mol Cancer Ther"},{"key":"BF2403905_CR15","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1046\/j.1365-2141.2000.02364.x","volume":"111","author":"M Ferlin","year":"2000","unstructured":"Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B . Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 2000; 111: 626\u2013634.","journal-title":"Br J Haematol"},{"key":"BF2403905_CR16","first-page":"6763","volume":"60","author":"Y Tu","year":"2000","unstructured":"Tu Y, Gardner A, Lichtenstein A . The phosphatidylinositol 3-kinase\/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 2000; 60: 6763\u20136770.","journal-title":"Cancer Res"},{"key":"BF2403905_CR17","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1182\/blood.V99.11.4138","volume":"99","author":"Yw Qiang","year":"2002","unstructured":"Qiang Yw, Kopantzev E, Rudikoff S . Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 2002; 99: 4138\u20134146.","journal-title":"Blood"},{"key":"BF2403905_CR18","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood.V96.8.2856","volume":"96","author":"Nl Ge","year":"2000","unstructured":"Ge Nl, Rudikoff S . Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96: 2856\u20132861.","journal-title":"Blood"},{"key":"BF2403905_CR19","first-page":"3876","volume":"62","author":"M Akiyama","year":"2002","unstructured":"Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 2002; 62: 3876\u20133882.","journal-title":"Cancer Res"},{"key":"BF2403905_CR20","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/sj.bjc.6601613","volume":"90","author":"E Menu","year":"2004","unstructured":"Menu E, Kooijman R, Van Valckenborgh E, Asosingh K, Bakkus M, Van Camp B et al. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer 2004; 90: 1076\u20131083.","journal-title":"Br J Cancer"},{"key":"BF2403905_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S1535-6108(04)00051-0","volume":"5","author":"C Garcia-Echeverria","year":"2004","unstructured":"Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 231\u2013239.","journal-title":"Cancer Cell"},{"key":"BF2403905_CR22","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","volume":"64","author":"R Fonseca","year":"2004","unstructured":"Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546\u20131558.","journal-title":"Cancer Res"},{"key":"BF2403905_CR23","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1182\/blood-2004-10-3913","volume":"105","author":"S Trudel","year":"2005","unstructured":"Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 2005; 105: 2941\u20132948.","journal-title":"Blood"},{"key":"BF2403905_CR24","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2002-11-3514","volume":"101","author":"N Mitsiades","year":"2003","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055\u20134062.","journal-title":"Blood"},{"key":"BF2403905_CR25","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"18","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 18: 1565\u20131571.","journal-title":"N Engl J Med"},{"key":"BF2403905_CR26","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.V98.2.492","volume":"98","author":"B Barlogie","year":"2001","unstructured":"Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492\u2013494.","journal-title":"Blood"},{"key":"BF2403905_CR27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.4065\/75.9.897","volume":"75","author":"SV Rajkumar","year":"2000","unstructured":"Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000; 75: 897\u2013901.","journal-title":"Mayo Clin Proc"},{"key":"BF2403905_CR28","first-page":"404","volume":"86","author":"M Hus","year":"2001","unstructured":"Hus M, Dmoszynska A, Soroka-Wojtaszko M, Jawniak D, Legiec W, Ciepnuch H, et al., Polish Multiple Myeloma Study Group. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001; 86: 404\u2013408.","journal-title":"Haematologica"},{"key":"BF2403905_CR29","first-page":"3377","volume":"8","author":"K Neben","year":"2002","unstructured":"Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377\u20133382.","journal-title":"Clin Cancer Res"},{"key":"BF2403905_CR30","first-page":"408","volume":"87","author":"P Tosi","year":"2002","unstructured":"Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F et al. Salvage therapy with thalidomide in patients with advanced relapsed\/refractory multiple myeloma. Haematologica 2002; 87: 408\u2013414.","journal-title":"Haematologica"},{"key":"BF2403905_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1182\/blood-2002-09-2846","volume":"102","author":"L Mileshkin","year":"2003","unstructured":"Mileshkin L, Biagi JJ, Mitchell P, Underhill C, Grigg A, Bell R et al. Multicenter phase 2 trial of thalidomide in relapsed\/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102: 69\u201377.","journal-title":"Blood"},{"key":"BF2403905_CR32","first-page":"399","volume":"86","author":"A Palumbo","year":"2001","unstructured":"Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399\u2013403.","journal-title":"Haematologica"},{"key":"BF2403905_CR33","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1023\/A:1011132808904","volume":"12","author":"MA Dimopoulos","year":"2001","unstructured":"Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991\u2013995.","journal-title":"Ann Oncol"},{"key":"BF2403905_CR34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1046\/j.1365-2141.2003.04473.x","volume":"122","author":"MH Kropff","year":"2003","unstructured":"Kropff MH, Lang N, Bisping G, Domine N, Innig G, Hentrich M et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003; 122: 607\u2013616.","journal-title":"Br J Haematol"},{"key":"BF2403905_CR35","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1200\/JCO.2003.01.055","volume":"21","author":"CK Lee","year":"2003","unstructured":"Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732\u20132739.","journal-title":"J Clin Oncol"},{"key":"BF2403905_CR36","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","volume":"15","author":"SV Rajkumar","year":"2001","unstructured":"Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15: 1274\u20131276.","journal-title":"Leukemia"},{"key":"BF2403905_CR37","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","volume":"20","author":"SV Rajkumar","year":"2002","unstructured":"Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319\u20134323.","journal-title":"J Clin Oncol"},{"key":"BF2403905_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","volume":"21","author":"D Weber","year":"2003","unstructured":"Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R . Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16\u201319.","journal-title":"J Clin Oncol"},{"key":"BF2403905_CR39","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/sj.leu.2402866","volume":"17","author":"SV Rajkumar","year":"2003","unstructured":"Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775\u2013779.","journal-title":"Leukemia"},{"key":"BF2403905_CR40","unstructured":"Palumbo A, Bertola A, Musto P, Pregno P, Bringhen S, Rus C et al. Oral melphalan, prednisone and thalidomide for multiple myeloma. Cancer, in press."},{"key":"BF2403905_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2005-02-0522","volume":"106","author":"M Cavo","year":"2005","unstructured":"Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35\u201339.","journal-title":"Blood"},{"key":"BF2403905_CR42","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","volume":"98","author":"M Zangari","year":"2001","unstructured":"Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614\u20131615.","journal-title":"Blood"},{"key":"BF2403905_CR43","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1182\/blood-2002-01-0335","volume":"100","author":"M Zangari","year":"2002","unstructured":"Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168\u20131171.","journal-title":"Blood"},{"key":"BF2403905_CR44","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063\u20133067.","journal-title":"Blood"},{"issue":"Suppl 1","key":"BF2403905_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0305-7372(03)00080-X","volume":"29","author":"P Richardson","year":"2003","unstructured":"Richardson P . Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 2003; 29 (Suppl 1): 33\u201339.","journal-title":"Cancer Treat Rev"},{"key":"BF2403905_CR46","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487\u20132498.","journal-title":"N Engl J Med"},{"key":"BF2403905_CR47","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.leukres.2004.11.004","volume":"29","author":"MH Kropff","year":"2005","unstructured":"Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005; 29: 587\u2013590.","journal-title":"Leuk Res"},{"key":"BF2403905_CR48","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/j.1365-2141.2005.05519.x","volume":"129","author":"HE Oakervee","year":"2005","unstructured":"Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M et al. PAD combination therapy (PS-341\/bortezomid, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 725\u2013762.","journal-title":"Br J Haematol"},{"key":"BF2403905_CR49","doi-asserted-by":"publisher","first-page":"7764","DOI":"10.1111\/j.1365-2141.2005.05540.x","volume":"129","author":"S Jagannath","year":"2005","unstructured":"Jagannath S, Durie BGM, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomid therapy alone and in combination with dexamethasone for patients with previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 7764\u20137783.","journal-title":"Br J Haematol"},{"key":"BF2403905_CR50","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","volume":"340","author":"R Lahtinen","year":"1992","unstructured":"Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I . Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992; 340: 1049\u20131052.","journal-title":"Lancet"},{"key":"BF2403905_CR51","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/sj.leu.2403693","volume":"19","author":"S Mariani","year":"2005","unstructured":"Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 2005; 19: 664\u2013670.","journal-title":"Leukemia"},{"key":"BF2403905_CR52","first-page":"5","volume":"87","author":"J Berenson","year":"1996","unstructured":"Berenson J . Pamidronate in the treatment of osteolytic bone lesions in multiple myeloma patients \u2013 the American experience. Br J Clin Pract Suppl 1996; 87: 5\u20137.","journal-title":"Br J Clin Pract Suppl"},{"key":"BF2403905_CR53","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1182\/blood-2003-02-0444","volume":"102","author":"RK Dasgupta","year":"2003","unstructured":"Dasgupta RK, Adamson PJ, Davies FE, Rollinson S, Roddam PL, Ashcroft AJ et al. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 2003; 102: 2345\u20132350.","journal-title":"Blood"},{"key":"BF2403905_CR54","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/sj.leu.2403541","volume":"19","author":"MJ Borad","year":"2005","unstructured":"Borad MJ, Swift R, Berenson JR . Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma. Leukemia 2005; 19: 154\u2013156.","journal-title":"Leukemia"},{"key":"BF2403905_CR55","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1182\/blood-2004-04-1670","volume":"104","author":"M Chatterjee","year":"2004","unstructured":"Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC . Combined disruption of both the MEK\/ERK and the IL-6R\/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004; 104: 3712\u20133721.","journal-title":"Blood"},{"key":"BF2403905_CR56","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","volume":"19","author":"S Wuilleme-Toumi","year":"2005","unstructured":"Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005; 19: 1248\u20131252.","journal-title":"Leukemia"},{"key":"BF2403905_CR57","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1470-2045(03)01076-3","volume":"4","author":"AJ Ashcroft","year":"2003","unstructured":"Ashcroft AJ, Davies FE, Morgan GJ . Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol 2003; 4: 284\u2013292.","journal-title":"Lancet Oncol"},{"key":"BF2403905_CR58","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1034\/j.1600-065X.2003.00035.x","volume":"194","author":"K Vanderkerken","year":"2003","unstructured":"Vanderkerken K, Asosingh K, Croucher P, Van Camp B . Multiple myeloma biology: lessons from the 5TMM models. Immunol Rev 2003; 194: 196\u2013206.","journal-title":"Immunol Rev"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2403905.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403905","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403905.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T23:29:55Z","timestamp":1683156595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2403905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,11]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,10,1]]}},"alternative-id":["BF2403905"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2403905","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,11]]},"assertion":[{"value":"6 April 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}